JNJ — Johnson & Johnson Share News
0.000.00%
Last trade - 00:00- $610.38bn
- $638.66bn
- $94.19bn
Lawyers in Alabama's TikTok settlement set to earn $14 million
Brief: J&J Says Tremfya Meets Primary And Major Secondary Endpoints In Axial PsA Study
Brief: Single Infusion Of Carvykti Delivered Five-Year Treatment-Free Remissions In 50% Of Patients In Early Line Relapsed/Refractory Multiple Myeloma
Advisory: Alert on EOG CFO appointment incorrectly tagged to J&J withdrawn
Brief: J&J Says New Model-Based Analysis Further Supports The Potential Of Tecvayli Plus Darzalex Faspro
Amgen's autoimmune drug succeeds in late-stage trial (updated)
Corrected: Amgen's autoimmune drug succeeds in late-stage trial
J&J's Caplyta meets main goal of bipolar mania study
Brief: CAPLYTA(Lumateperone)Shows Significant And Rapid Improvement In Bipolar Mania In Pivotal Phase 3 Study
Health Rounds: New dye for MRI exams detects lung cancer earlier
Contineum falls as J&J-partnered depression drug fails mid-stage trial
Live Markets: From Ozempic Face to K-Beauty Factories: The Next Beauty Bet
Explainer: As Trump backs psychedelics research, FDA weighs safety and access standards
Live Markets: Autumn in New York: Factory expansion slows, input prices at multi-year highs - Empire State
Live Markets: US stock indexes swing lower as oil, yields jump
Brief: JNJ Reports Low Rates Of Treatment-Related Events For Rybrevant Faspro Plus Lazcluze At Wclc 2026
Contineum, J&J's depression drug fails to meet mid-stage trial goal (updated)
Contineum, J&J's depression drug fails to meet mid-stage trial goal
U.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics